March 3, 2017: Triple negative breast cancer (TNBC) represents a relatively small proportion — 15 percent — of all breast cancers. Yet a great deal of attention has been given to TNBC in recent years. While targeted therapies have been developed for breast cancers expressing estrogen receptor, progesterone receptor, and human epidermal growth factor receptor… Read More
The post New study combines CDK and androgen receptor inhibitors in triple negative breast cancer appeared first on Big Ten Cancer Research Consortium.
Read the full article at: https://www.bigtencrc.org/new-study-combines-cdk-and-androgen-receptor-inhibitors-in-triple-negative-breast-cancer/